Follow the Money to Medical Devices & Diagnostics
Spotlight on Ivantis, Inc.

by

Follow the Money to Medical Device & Diagnostic Opportunities highlights a newly funded medical device or diagnostic company. This includes important insights into the featured company’s product pipeline, manufacturing and business relationships, and likely sourcing opportunities.

Ivantis is a U.S. private company that develops solutions for the treatment of glaucoma. It raised $25 million in a completion of a Series C venture capital investment as reported in the PharmSource Lead Sheet on January 12, 2017.

Corporate Highlights

  • Ivantis was founded in 2007
  • Corporate Headquarters: Irvine, CA

Sourcing Opportunities

  • Ivantis plans to use the proceeds to support US approval and commercialization efforts for the Hydrus Microstent.

Device: Hydrus Microstent™
Development Phase: Pivotal Studies
Medical Specialty: Ophthalmology
Purpose: Device – Therapeutic/Interventional
Type: Implant – Stent
Description: A nitinol microstent designed to relieve high intraocular pressure, commonly caused by primary open angle glaucoma.

Approvals/Clearances:
US – PMA planned
EU – CE Mark approval
Australia – TGA approval

Previous Financings

  • September 2014: $25 million in a completed venture capital investment
  • January 2014: $14 million in a completed venture capital investment
  • August 2013: $5 million in a completed venture capital investment
  • February 2013: $27 million in a completed venture capital investment

Medical Device & Diagnostics Pipeline1

Product Candidate Indication Medical Specialty Purpose Type Status
Hydrus Microstent Glaucoma Ophthalmology Device – Therapeutic/Interventional Implant – Stent Pivotal Studies

Regulatory Approvals and Clearances

Product Candidate Region Approval/Clearance Year of Approval or Clearance
Hydrus Microstent Australia TGA 2013
Hydrus Microstent EU CE Mark 2011

1Source: PharmSource Lead Sheet

Contact Information

Ivantis, Inc. Key Officers
38 Discovery, Suite 150 Dave Van Meter, President & CEO
Irvine, CA 92618 USA Brett Trauthen, CSO
Phone: +1-949-600-9650 Ken Galt, VP, R&D
Fax: +1-949-600-9651 Gretchen Haig, Director, Clinical Research
Web: www.ivantisinc.com Gary Krasner, Senior Clinical Project Manager

Related posts:
Follow the Money to Medical Device & Diagnostic Opportunities – Spotlight on Femasys, Inc.
Follow the Money to Medical Device & Diagnostic Opportunities – Spotlight on Genalyte Inc.
Follow the Money to Medical Device & Diagnostic Opportunities – Spotlight on Bigfoot Biomedical

Scotty is a Research Analyst at PharmSource. He holds a BS degree in Biology from George Mason University and an MPH degree from Eastern Virginia Medical School. He’s experienced in data collection, analysis and management, and has done laboratory analysis and safety program development.

More posts by Scotty Chung-Siu